$CLDI Cashflow Statement | Understand Stock

$CLDI

$0.64 -$0.00 (0.76%) Close

$CLDI Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 9 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Changes in unrealized gain on marketable securities held in Trust Account
Interest income
Change in fair value of warrant liability
Change in fair value of forward purchase liability
Sponsor share repurchase financing expense
Allocation of deferred offering cost for warrant liability
Depreciation expense
Amortization of right of use assets
Depreciation and amortization expense
Amortization of debt discount and financing costs
Stock-based compensation
Change in fair value of debt, other liabilities, and derivatives
Series B convertible preferred stock financing costs
Debt extinguishment
Disposal of fixed assets
Legal settlement with shares of common stock
Change in fair value of other liabilities and derivatives
Gain on sale of investment in Nova Cell
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses
Accrued expenses
Accrued interest
Prepaid expenses and other current assets
Accounts payable
Accrued expenses and other current liabilities
Other noncurrent liabilities
Operating lease right of use liability

Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of investments
Purchases of machinery and equipment
Cash assumed in connection with the FLAG Merger
Security deposits, net
Cash disposed in sale of investment in Nova Cell
Net cash used in investing activities

CASH FLOWS FROM FINANCING ACTIVITIES:
Payments for underwriting fee
Proceeds from May Inducement Offer
Proceeds from public offerings
Proceeds from warrant inducement financing
Proceeds from registered direct offering
Proceeds from at the market offering
Proceeds from exercise of pre-funded warrants
Proceeds from exercise of stock options
Proceeds from exercise of common stock warrants
Proceeds from issuance of Series B convertible preferred stock
Related party proceeds from issuance of Series B convertible preferred stock
Nonrelated Party
Related Party
Total related party proceeds from issuance of Series B convertible preferred stock
Proceeds from Non-Redemption and PIPE Agreements
Proceeds from simple agreements for future equity (SAFE)
Proceeds from issuance of term notes payable
Related party proceeds from issuance of term notes payable
Repayment of financing lease obligations
Repayment of principal on term notes payable
Repayment of principal on related party bridge loan payable
Payment of financing costs
Repayment of principal on related party term notes payable
Payment of Class A common stock redemptions
Payment of deferred offering costs
Proceeds from issuance of noncontrolling interest in Nova Cell
Proceeds from issuance of convertible notes payable
Related party proceeds from issuance of bridge loans
Related party proceeds from issuance of loan payable
Proceeds from issuance of promissory note
Proceeds from issuance of common stock and warrants per subscription agreement
Repayment of convertible note payable
Payment of debt issuance costs
Net cash provided by financing activities

Net Change in Cash
Cash — Beginning of period
Cash — End of period
NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH
Effect of exchange rate changes on cash
NET (DECREASE) INCREASE IN CASH AND RESTRICTED CASH
At beginning of the year
At end of the year
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest
Cash paid for income taxes
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES
Initial measurement of Class A common stock subject to possible redemption
Accretion Of Class A Common Stock Subject To Possible Redemption
Remeasurement of Class A common stock subject to possible redemption
Initial fair value of public warrant liability
Initial fair value of private warrant liability
Initial fair value of forward purchase units liability
Initial measurement of contingent interest liability
Deferred underwriting fee payable
Issuance of common stock per convertible note conversion
Deemed dividend on warrants
Machinery and equipment acquired through financing leases
Deferred financing costs included in accounts payable and accrued liabilities
Financing fees included in accounts payable and accrued liabilities
Issuance of common stock per conversion of convertible note
Issuance of convertible note for legal settlement
Issuance of common stock in lieu of cash for services
Related party issuance of common stock in lieu of cash for services
Issuance of common stock and warrants for legal settlement
Debt discount on Convertible Notes
Issuance of common stock in lieu of cash for SEPA commitment fee
Financing fees
Issuance of restricted stock units for liability settlement
Issuance of common stock for deferred compensation settlement in connection with FLAG Merger
Issuance of warrants for deferred compensation settlement in connection with FLAG Merger
Issuance of common stock with term notes as interest paid in kind and other
Assumed liabilities from FLAG Merger
Assumed warrant liability from FLAG Merger
Issuance of common stock as a result of the FLAG Merger
Forward purchase agreement derivative asset
Financing fees in connection with FLAG Merger
Issuance of preferred stock upon conversion of related party convertible notes payable
Issuance of common stock upon conversion of convertible preferred stock
Issuance of SAFE in lieu of cash for advisory services
Issuance of common stock for Calidi debt settlement in connection with FLAG Merger
Issuance of SAFE in lieu of cash for settlement of advisory services accounts payable

Comments